

Haematic Antegrade Repriming procedure to initiate a safer cardiopulmonary bypass.

Blanco-Morillo J¹, Sornichero-Caballero A¹, Farina P², Arribas-Leal JM³, Puis 4⁴, Tormos Ruiz E¹, Verdú Verdú A¹, Cánovas-López SJ³.

¹ Cardiac Surgery Department. Perfusion Unit. Virgen de la Arrixaca University Hospital. Murcia. Spain.

² Cardiac Surgery Department. Agostino Gemelli university Policlinic. Rome. Italy.

³ Cardiac Surgery Department. Perfusion Unit. Virgen de la Arrixaca University Hospital. Murcia. Spain.

⁴ Cardiac Surgery Department. Perfusion Unit. Brussel University Hospital. Brussels. Belgium.

Keywords: Cardiopulmonary bypass, MiECC, minimized extracorporeal circuit, retrograde autologous priming, repriming techniques, vacuum assisted venous drainage, cardiac surgery.

Summary:

Background: Cardiopulmonary bypass is a safe technique frequently required in cardiac surgery. Despite that, it carries several undesired effects related to haemodilution, emboli and alterations on the coagulation and microcirculation. Different strategies like the minimized circuits (MiECC) or the retrograde autologous priming (RAP) have attempted to reduce its impact, but finally lead to inconsistent results as independent measures due to the heterogeneity on its practice. The haematic antegrade repriming (HAR) offers a standardized materials and methodology that could offer a reproducible method inspired in evidence-based recommendations. **Description of the technique:** HAR is performed in a standardized Class IV MiECC that is reprimed antegradely with autologous blood obtained from the aorta of the patient, before the cardiopulmonary bypass (CPB) initiation. Then, CPB is started with the support of vacuum assisted venous drainage (VAVD). **Discussion:** The strict application of HAR results in a fix haemodilution of 300ml of crystalloid priming, avoiding the sudden haemodilution and the crystalloid embolism of the CPB initiation. The synergic effect that converges in HAR could exceed the evidence-based benefits of RAP, MiECC and VAVD promising to improve the outcomes in terms of transfusion, complications, stay and survival. **Conclusion:** HAR is proposed as a new approach to increase the safety of the CPB. Its overall benefits should be properly assessed and validated by current and further studies.

Background

Cardiopulmonary bypass (CPB) offers the extracorporeal support required during most of cardiac surgery procedures but is also related to undesirable effects. Despite the remarkable evolution regarding to its practice, CPB still contributes to an insult related to the haemodilution, the embolic release and alterations of the coagulation and the microcirculation that hinders the postoperative recovery (1–3).

During CPB initiation, in a conventional setup, the blood of the patient is replaced by the priming volume of the circuit instantly and then, being mixed with the autologous blood, causes a sudden haemodilution that is even increased later with the administration of a cardioplegic solution. Haemodilution has been identified as the mechanism that triggers postoperative coagulopathy, inflammatory response, tissular hypoxia and higher blood products requirement until discharge (4,5). The anaemic status and the subsequent transfusion augment the risk of glomerular dysfunction, rising levels of troponin, length of ventilation time and hospital stay as well as the mortality by individual exposure. This effect is even amplified when both appear in combination (6).

Additionally, some studies identified a certain amount of gaseous microemboli that remain in the oxygenation chamber after the conventional crystalloid priming that represent a matter of concern. These emboli are released to the bloodstream during different stages of the cardiac surgery procedure like the initiation of CPB and variations in flow and pressure on the oxygenation chamber (7–9).

We performed a systematic review using Pubmed, Cochrane and Embase under the following search descriptors: (cardiopulmonary bypass) AND ((minimally invasive) OR (minimize impact)). A total of 1835 results were obtained. Only clinical trials, randomized controlled trials, meta-analyses and systematic reviews were considered, resulting in 78 articles that were studied.

Considering that most strategies to tackle the aforementioned problems, offer only partial solutions (7,8), or involve heterogeneous practices that do not result in overall benefits (10–16), we propose Haematic Antegrade Repriming (HAR) as standardized strategy to implement a higher level of safety through reproducible results.

This new strategy, based on reducing the surface and repriming the circuit with autologous blood was developed by the perfusion team. Afterwards, the protocol was presented and validated by the surgical department to be applied in every patient.

Description of the technique

After applying HAR to the standardized MiECC (17), under the purposed methodology, the haemodilutional impact is reduced to 300ml of priming volume. To guarantee its replicability, the following procedure is defined by 6 positions and simple manœuvres to be successfully accomplished (Fig.1):




Fig. 1. HAR procedure: the 6 positions that result in 300ml of haemodilution

Step 1: Venous line recovery: Starting in Pos.1, set VAVD to -30mmHg. Remove clamp A, collecting 300±50ml of crystalloid volume in the reservoir. Replace clamp A afterwards.

Step 2: Arterial line recovery: Starting in Pos.2, remove clamp B after arterial line connection to the aortic cannula.

Step 3: Repriming the arterial line: Remove clamp D, repriming the arterial line retrogradely until the recirculation line is primed with blood and clamp it back afterwards, avoiding the mixture of blood and crystalloid in the reservoir. The mean arterial pressure should be maintained above 60mmHg (MAP>60mmHg). In this manoeuvre, 50-80 ml of additional crystalloid are collected.

Step 4*: Priming withdrawal: When using a centrifugal pump (CP), increase the flow up to 2000rpm, then open clamp E. If using a roller pump (RP), first open clamp E, then set the flow rate to 250-500ml/min. This should displace the crystalloid volume contained in the reservoir towards the collector bag until there is no crystalloid volume in the reservoir (zero level).

Step 5*: Arterial "sequestration": Place Clamp F on the base of the reservoir to prevent blood from mixing with the crystalloid solution during "sequestration". Then, open clamp D gently (maintain a backflow between 100 and 300 ml/min, MAP>60mmHg) until 300-400ml of blood are obtained in the reservoir. Close clamp D afterwards.

Step 6*: Antegrade repriming: If using a CP, remove clamp F and increase the flow to 2000rpm, then open clamp E to reprime the circuit. If using a RP, first open Clamps F and E to avoid system over-pressurization, then initiate a 250-500ml/min flow. Antegrade repriming should

be performed until the blood reaches the collector bag to maximize benefits. Once HAR is complete, ensure that clamp D and clamp E are closed. The 3-way stopcock H must also be closed, blocking flow to the collector bag.

*Steps 4, 5 and 6 are performed during the venous cannulation.

To initiate the CPB, set VAVD to -30mmHg and remove clamp A. If using a CP: raise the pump speed to 1500 rpm, remove clamp C and continue increasing CP speed to the target flow. If using a RP: remove clamp C and initiate perfusion progressively up to the target flow.

When the procedure is applied, the coordination between the anaesthesiologist, the perfusionist and the surgeon should be maximized. During the "sequestration", the mean arterial pressure (MAP) has to be maintained ≥ 60 mmHg. If brain near-infrared spectroscopy is available, saturation reductions over 15% of baseline should be avoided. If hypotension is observed, the Trendelenburg position and/or short-term α -agonist administration like phenylephrine (0.01-0.03mg I.V. bolus) could be applied as offset measures.

While HAR is being performed, venous cannulae placement should be verified by means of transesophageal echography to guarantee proper drainage.

Discussion

Strict application of the HAR protocol, allows us to obtain a fixed, reproducible and safe result, through the combined use of miniaturized extracorporeal circulation - MiECC, retrograde autologous priming - RAP and vacuum assisted venous drainage - VAVD. The benefits obtained from that combination potentially exceeds the benefits from the use of a standalone measure in terms of blood saving, complications, length of stay and survival (18,19)-

Minimization of the circuit surface (MiECC Class IV) reduces the inflammatory response, blood product exposure, haemodilution, and coagulopathy after surgery (4,20,21).

RAP and its multiple variations have offered a significant reduction of haemodilution while other authors offer less homogenous results (14,18,22). With this regard, strict application of the HAR technique on the standardized circuit design (17), offers a fix and reproducible haemodilution of only 300ml; that is lower than referred by any other study in an adult circuit.

Furthermore, during the CPB initiation in a conventional setup ,the remaining microemboli that might persist in the oxygenation chamber are displaced by blood, with a subsequent release to the bloodstream (7,8). The application of HAR could potentially reduce the amount of bubbles because they are being displaced to the collector bag during the procedure. Observable benefits in organs and microcirculation are expected due to the decrease of the embolic aggression (3,5,23).

The inclusion of VAVD has been related to a reduction of postoperative blood transfusions without any major complication if the suction pressure is not lower than -40mmHg. More negative pressures should be avoided because they do not confer any benefit and could result in haemolysis and embolism (24,25).

HAR represents more than only a perfusion technique; it requires the full coordination of the surgical team during a short period of time. Once the learning curve is overcome, HAR may offer significant benefits that will be audited in further studies. As is the case during any other

clinical procedure implementation, to decrease the associated risks of the learning curve, a proctored and/or multimedia training of the team should be applied (26).

Limitations and Special Considerations of the Procedure

An absolute limitation to its application is that, if uncontrollable hemodynamic instability during cannulation occurs, CPB should be initiated even if it requires aborting HAR before it is completed.

After completion of HAR, if it turns out to be impossible to achieve target flow during the CPB, consider a vasoplegic syndrome linked to CPB (27). If vasoplegia is confirmed, prioritize the optimization of vascular resistance with vasoactive drugs and consider the infusion of crystalloid volume as a last resource if needed.

Conclusion

HAR represents a standardized method to decrease the impact of sudden haemodilution and emboli load related to CPB initiation by repriming of the circuit with autologous blood. Further studies will be carried out to validate the procedure and focus on the promising benefits of combining RAP, MiECC and VAD, thereby minimizing haemodilution to 300ml.

Disclosures:

This article has been constructed without any sponsorship or conflict of interest.

Acknowledgements:

To Mr. Vicente Alambiaga†, Mrs. M^{re} Ángeles Bruño, Mr. Gustavo Llobet and Mr. Francisco Mena, as my menthors, and to all the professionals since Mary and John Gibbon that have contributed to the evolution of the cardiopulmonary bypass and the perfusion science.

Bibliography

1. Ranucci M, Baryshnikova E, Ciotti E, Ranucci M, Silvetti S, Surgical and Clinical Outcome REsearch (SCORE) Group. Hemodilution on Cardiopulmonary Bypass: Thromboelastography Patterns and Coagulation-Related Outcomes. *J Cardiothorac Vasc Anesth.* 2017;31(5):1588-94.
2. Giacinto O, Satriano U, Nenna A, Spadaccio C, Lusini M, Mastroianni C, et al. Inflammatory Response and Endothelial Dysfunction Following Cardiopulmonary Bypass: Pathophysiology and Pharmacological Targets. *Recent Pat Inflamm Allergy Drug Discov.* 2019;
3. Myers GJ, Wegner J. Endothelial Glycocalyx and Cardiopulmonary Bypass. *J Extra Corpor Technol.* 2017;49(3):174-81.
4. Ranucci M, Baryshnikova E. Inflammation and coagulation following minimally invasive extracorporeal circulation technologies. *J Thorac Dis.* 2019;11(Suppl 10):S1480-8.
5. Hare GMT, Han K, Leshchynshyn Y, Mistry N, Kei T, Dai SY, et al. Potential biomarkers of tissue hypoxia during acute hemodilutional anemia in cardiac surgery: A prospective

- study to assess tissue hypoxia as a mechanism of organ injury. *Can J Anaesth.* 2018;65(8):901-13.
6. Loor G, Rajeswaran J, Li L, Sabik JF, Blackstone EH, McCrae KR, et al. The least of 3 evils: Exposure to red blood cell transfusion, anemia, or both? *The Journal of Thoracic and Cardiovascular Surgery.* 2013;146(6):1480-1487.e6.
 7. Husebråten IM, Fiane AE, Ringdal M-AIL, Thiara APS. Measurement of gaseous microemboli in the prime before the initiation of cardiopulmonary bypass. *Perfusion.* 2018;33(1):30-5.
 8. Stehouwer MC, de Vroege R, Hoohekerk GJF, Hofman FN, Kelder JC, Buchner B, et al. Carbon Dioxide Flush of an Integrated Minimized Perfusion Circuit Prior to Priming Prevents Spontaneous Air Release Into the Arterial Line During Clinical Use. *Artif Organs.* 2017;41(11):997-1003.
 9. Blanco-Morillo JB, López SC, Ruiz ET, Verdú AV, Caballero AS, Molina MM, et al. Embolia: el enemigo silente. Estudio multicéntrico anónimo para la descripción de eventos embólicos evitables en circulación extracorpórea. *Revista de la Asociación Española de Enfermería Quirúrgica.* 2018;(41):55-63.
 10. Panico FG, Neptune WB. A mechanism to eliminate the donor blood prime from the pump-oxygenator. *Surg Forum.* 1960;10:605-9.
 11. Rosengart TK, DeBois W, O'Hara M, Helm R, Gomez M, Lang SJ, et al. Retrograde Autologous Priming For Cardiopulmonary Bypass: A Safe And Effective Means Of Decreasing Hemodilution And Transfusion Requirements. *The Journal of Thoracic and Cardiovascular Surgery.* 1998;115(2):426-39.
 12. Balachandran S, Cross MH, Karthikeyan S, Mulpur A, Hansbro SD, Hobson P. Retrograde autologous priming of the cardiopulmonary bypass circuit reduces blood transfusion after coronary artery surgery. *The Annals of Thoracic Surgery.* 2002;73(6):1912-8.
 13. Hagedorn C, Glogowski K, Valleley M, McQuiston L, Consbruck K. Retrograde Autologous Priming Technique to Reduce Hemodilution during Cardiopulmonary Bypass in the Pediatric Cardiac Patient. *J Extra Corpor Technol.* 2019;51(2):100-3.
 14. Murphy GS, Szokol JW, Nitsun M, Alspach DA, Avram MJ, Vender JS, et al. The failure of retrograde autologous priming of the cardiopulmonary bypass circuit to reduce blood use after cardiac surgical procedures. *Anesth Analg.* 2004;98(5):1201-7, table of contents.
 15. Starinieri P, Declercq PE, Robic B, Yilmaz A, Van Tornout M, Dubois J, et al. A comparison between minimized extracorporeal circuits and conventional extracorporeal circuits in patients undergoing aortic valve surgery: is «minimally invasive extracorporeal circulation» just low prime or closed loop perfusion ? *Perfusion.* julio de 2017;32(5):403-8.
 16. Vranken NP, Babar ZU, Montoya JA, Weerwind PW. Retrograde autologous priming to reduce allogeneic blood transfusion requirements: a systematic review. *Perfusion.* 2020;267659119895474.

17. Blanco-Morillo J, Sornichero-Caballero A, Arribas-Leal JM, Verdú Verdú A, Tormos-Ruiz E, Farina P, et al. Description of the Minimized Extracorporeal Circuit to perform Haematic Antegrade Repriming in Cardiopulmonary Bypass. 2020; Available at: <https://zenodo.org/record/4273689#.X6-0hchKgRk>
18. Puis L, Milojevic M, Boer C, De Somer FMJJ, Gudbjartsson T, van den Goor J, et al. 2019 EACTS/EACTA/EBCP guidelines on cardiopulmonary bypass in adult cardiac surgery. *Interact CardioVasc Thorac Surg* [Internet]. 2019; Available at: <https://academic.oup.com/icvts/advance-article/doi/10.1093/icvts/ivz251/5579824>
19. Menkis AH, Martin J, Cheng DCH, Fitzgerald DC, Freedman JJ, Gao C, et al. Drug, devices, technologies, and techniques for blood management in minimally invasive and conventional cardiothoracic surgery: a consensus statement from the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) 2011. *Innovations (Phila)*. 2012;7(4):229-41.
20. Anastasiadis K, Murkin J, Antonitsis P, Bauer A, Ranucci M, Gygax E, et al. Use of minimal invasive extracorporeal circulation in cardiac surgery: principles, definitions and potential benefits. A position paper from the Minimal invasive Extra-Corporeal Technologies international Society (MiECTIS). *Interact Cardiovasc Thorac Surg*. 2016;22(5):647-62.
21. Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Ferraris VA, Brown JR, Despotis GJ, Hammon JW, Reece TB, et al. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. *Ann Thorac Surg*. 2011;91(3):944-82.
22. Hensley NB, Gyi R, Zorrilla-Vaca A, Choi CW, Lawton JS, Brown CH, et al. Retrograde Autologous Priming in Cardiac Surgery: Results From a Systematic Review and Meta-analysis. *Anesth Analg*. 2020;
23. Wu Q, Gao W, Zhou J, He G, Ye J, Fang F, et al. Correlation between acute degradation of the endothelial glycocalyx and microcirculation dysfunction during cardiopulmonary bypass in cardiac surgery. *Microvasc Res*. 2019;124:37-42.
24. Gao S, Li Y, Diao X, Yan S, Liu G, Liu M, et al. Vacuum-assisted venous drainage in adult cardiac surgery: a propensity-matched study. *Interact Cardiovasc Thorac Surg*. 2019;
25. Carvalho Filho EB de, Marson FA de L, Costa LNG da, Antunes N. Vacuum-assisted drainage in cardiopulmonary bypass: advantages and disadvantages. *Rev Bras Cir Cardiovasc*. 2014;29(2):266-71.
26. Shim JS, Kim JY, Pyun JH, Cho S, Oh MM, Kang SH, et al. Comparison of effective teaching methods to achieve skill acquisition using a robotic virtual reality simulator: Expert proctoring versus an educational video versus independent training. *Medicine (Baltimore)*. 2018;97(51):e13569.
27. Busse LW, Barker N, Petersen C. Vasoplegic syndrome following cardiothoracic surgery—review of pathophysiology and update of treatment options. *Crit Care* [Internet]. 2020;24. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001322/>